Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US review and approval news for the week in brief: It didn't take the Food and Drug Administration long to approve the first novel drug of 2020 (and the new decade), with the honor going to Blueprint Medicines Corp.'s targeted gastrointestinal stromal tumor (GIST) drug Ayvakit (avapritinib).

A notable supplemental approval went to Merck & Co. Inc.'s PD-1 inhibitor Keytruda (pembrolizumab) for a high-risk bladder cancer...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers